#AnaB hashtag - Bluesky

4 days ago

First Tracks targets $180M cash at launch after $145M financing $80M of the financing goes to the company, supporting ANB033 development and a two-year cash runway. The spin-off is expected to close on April 20.

#ANAB First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

www.stocktitan.net/news/ANAB/first-tracks-b...

0 0 0 0

StockTitan

@stocktitan.net

4 days ago

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update Anaptys (NASDAQ: ANAB) announced a $100 million stock repurchase plan and a business update ahead of the planned spin-off of First Tracks Biotherapeutics (TRAX) targeted for April 20, 2026. Post-spin-off, Anaptys will manage royalty and financial collaborations for Jemperli and imsidolimab, operate with ~10 FTEsannualized expenses <$10M and initial net cash and investments of approximately $140–$145M.The company appointed Susannah Gray to the board, engaged Piper Sandler as exclusive financial advisor, and anticipates paying down remaining non-recourse debt to Sagard by end of Q2 2027.

#ANAB Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

StockTitan

@stocktitan.net

3 weeks ago

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results Anaptys (Nasdaq: ANAB) announced a planned Q2 2026 spin-off of its biopharma portfolio into a new public company, First Tracks Biotherapeutics (TRAX), while retaining a royalty-management company under the Anaptys name.Key financials: year-end cash and investments of $311.6M, Q4 2025 net income of $49.6M, and full-year 2025 net loss of $13.2M. Jemperli sales reached $343M in Q4 2025, implying a ~$1.4B annualized run rate and potential >$390M annualized royalties to Anaptys at GSK peak guidance.

#ANAB Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/ANAB/anaptys-provid...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary {"summary":"","positive":[],"negative":[],"faq":[]}

#ANAB Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

www.stocktitan.net/news/ANAB/anaptys-files-...

0 0 0 0

Ersties

@ersties-fan.bsky.social

3 months ago

Laney & Ana B @ Ersties
www.free-abbywinters.com/Laney-Ana-B....
#Laney #AnaB #Ersties

9 1 0 0

StockTitan

@stocktitan.net

3 months ago

#ANAB #VNDA Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

www.stocktitan.net/news/ANAB/vanda-announce...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Anaptys Announces Participation in December Investor Conferences Anaptys (Nasdaq: ANAB) said CEO Daniel Faga and other executives will participate in multiple December investor conferences, including a fireside chat and 1x1 meetings at the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 1:30 PM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 3, 2025 at 7:55 AM ET.Live webcasts of the fireside chats will be available on the company investor website and replays will be available for at least 30 days after each event.

#ANAB Anaptys Announces Participation in December Investor Conferences

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

JUST IN: ( NASDAQ: #ANAB ) Anaptys Announces $100 Million Stock Repurchase Plan

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Anaptys Announces $100 Million Stock Repurchase Plan AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may

#ANAB Anaptys Announces $100 Million Stock Repurchase Plan

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#ANAB Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update Anaptys (Nasdaq: ANAB) reported Q3 2025 results and announced intent to separate its biopharma operations from its royalty management business by year-end 2026 to unlock value across two public companies. The company expects to accrue a one-time $75 million commercial milestone in Q4 2025 when GSK's Jemperli reaches $1 billion in worldwide sales and cites >$390 million in annualized royalties at GSK peak-sales guidance of >$2.7 billion.Operationally, Anaptys highlighted rosnilimab Phase 2b RA data and expects top-line Week-12 UC Phase 2 data in Nov/Dec 2025; ANB033 Phase 1b in celiac initiated with data expected in Q4 2026. Cash and investments were $256.7 million at Sept 30, 2025, with ~3.34M shares repurchased (~10.9% outstanding) for $65.2 million.

#ANAB Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Anaptys Announces Participation in November Investor Conferences Anaptys (NASDAQ: ANAB) said CEO Daniel Faga and other executives will participate in multiple investor conferences in November 2025, including TD Cowen Immunology & Inflammation Summit (virtual) on Nov 12, 2025 at 8:00 AM ET, Guggenheim Healthcare Innovation Conference (Boston) on Nov 12, 2025 at 11:30 AM ET, Stifel Healthcare Conference (New York) on Nov 13, 2025 at 1:20 PM ET, and Jefferies Global Healthcare Conference (London) on Nov 17, 2025 at 4:00 PM GMT.Live webcasts and replays (available for at least 30 days) will be posted on Anaptys’ investor presentations and events page.

#ANAB Anaptys Announces Participation in November Investor Conferences

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKs New data confirm durable clinical benefit across multiple higher-order response

#ANAB Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Leading Indicators, Tuesday October 21, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Tue Oct 21st - #MIGI #APLM #XNCR #ANDE #ANAB #IDA #MUX - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 Anaptys (NASDAQ: ANAB) announced that complete Phase 2b data for rosnilimab in rheumatoid arthritis will be presented as a late-breaking oral at ACR Convergence 2025 in Chicago on Oct 29, 2025 from 8:00–9:30am CT.The company described rosnilimab as a pathogenic T cell depleter that produced a compelling safety and tolerability profile and JAK-like efficacy through six months, with effects that were reported as durable for at least three months off-drug. Paul Emery, M.D., University of Leeds, will present (Abstract ID 2215555). The presentation will be available for download from the company website after the session.

#ANAB Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 AnaptysBio (NASDAQ:ANAB) announced plans to split into two independent, publicly traded companies by year-end 2026. The first entity, temporarily named Royalty Management Co, will manage royalties from collaborations including GSK's Jemperli (generating $482M in 1H 2025) and Vanda's imsidolimab. The second entity, Biopharma Co, will focus on developing immunology therapeutics, including rosnilimab, ANB033, and ANB101.Key financials include Jemperli's tiered royalties of 8-25% on net sales, with GSK projecting peak sales of £2 billion ($2.7B). The Vanda collaboration could yield up to $35M in milestones plus 10% royalties. Current Jemperli royalties are directed to Sagard until reaching $600M by 2031 or $675M thereafter, with an estimated $250M accrued through 2025.

#ANAB Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

ANAB Launches Digital Technology Initiative and AI Task Force for Enhanced Accreditation Processes ANAB has unveiled its Digital Technology Initiative aimed at transforming accreditation processes through AI-driven solutions, enhancing client experience across the board.

ANAB Launches Digital Technology Initiative and AI Task Force for Enhanced Accreditation Processes #USA #New_York #ANAB #Digital_Technology #AI_Task_Force

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Biotech Firm AnaptysBio Announces Triple Conference Schedule: Cantor, Wells Fargo & Stifel Events in September Clinical-stage biotech AnaptysBio to participate in Cantor, Wells Fargo, and Stifel healthcare conferences this September. CEO Daniel Faga to lead fireside chats with investor meetings.

#ANAB Anaptys Announces Participation in September Investor Conferences

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

AnaptysBio Reports Positive Six-Month Data for Potential Best-in-Class Rheumatoid Arthritis Therapy Phase 2b trial shows durable clinical responses, favorable safety, and monthly dosing convenience AnaptysBio (Nasdaq: ANAB) announced new six-month data from

#ANAB has reported positive six-month data for its potential best-in-class RA therapy, showing strong efficacy and safety. A hopeful step forward for millions living with chronic inflammation.
#AnaptysBio
prismmarketview.com/anaptysbio-r...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

New Rheumatoid Arthritis Drug Achieves JAK-Like Efficacy with Better Safety Profile in Phase 2b Trial Latest clinical data reveals monthly dosing success with durable responses lasting 2+ months off treatment. See impressive 69% low disease activity achievement rate.

#ANAB Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

www.stocktitan.net/news/ANAB/anaptys-announ...

0 0 0 0

SocratesAgainstFascism

9 months ago

0 0 0 0

10 months ago

New PD-1 Drug Trial Data: Rosnilimab Shows Promise for Rheumatoid Arthritis Treatment - Key Results Coming Latest Phase 2b RENOIR trial data reveals rosnilimab's performance as a novel PD-1 depleter for rheumatoid arthritis. Join expert discussion with leading researchers. Get insights.

#ANAB Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

www.stocktitan.net/news/ANAB/anaptys-to-ann...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago